内容紹介
Clinical Experience of S-1 and Oxaliplatin(SOX)as the First-Line Chemotherapy for Metastatic/Recurrent Gastric Cancer
Summary
We retrospectively investigated the efficacy and safety of S-1 and oxaliplatin(SOX)as the first-line chemotherapy in patients with metastatic/recurrent gastric cancer. A total of 27 patients who received SOX as the first-line chemotherapy in our hospital were considered for the study. The SOX chemotherapy schedule consisted of 1 course every 3 weeks. S-1 was administered orally, at 80-120 mg-body, every day for 14 days. Oxaliplatin was infused at 100 mg/m2 on day 1 of each course. The median number of treatment courses was 7. The response rate and disease control rate were 47.6% and 76.2%, respectively. The observed adverse events of Grade 3 or more included neutropenia(33.3%); peripheral neuropathy and anorexia(11.1%); thrombocytopenia(7.4%); and anemia, diarrhea, fatigue, and hypercalcemia(3.7%). The median overall survival was not achieved, and the 1-year survival rate was 63.2%. Therefore, SOX is an effective and feasible first-line chemotherapy that is easily available for ambulatory treatment of patients with metastatic/recurrent gastric cancer.
要旨
進行再発胃癌に対する一次治療としてのS-1+oxaliplatin(SOX)療法の有効性と安全性について検討した。対象は当科でSOX療法を施行した進行再発胃癌27例である。投与方法はoxaliplatin 100 mg/m2を第1日目に点滴静注,S-1 80～120 mg/bodyを2週投与1週休薬で投与し,3週1コースとした。投与コース中央値は7コースで,奏効率47.6%,病勢コントロール率は76.2%であった。Grade 3以上の有害事象は,好中球減少33.3%,末梢神経障害,食欲不振11.1%,血小板減少7.4%,貧血,下痢,疲労,高カルシウム血症を3.7%に認めた。生存期間中央値には到達せず,1年生存率は63.2%であった。実地臨床においてもSOX療法の治療効果は良好で,外来で安全に施行可能であった。
目次
Summary
We retrospectively investigated the efficacy and safety of S-1 and oxaliplatin(SOX)as the first-line chemotherapy in patients with metastatic/recurrent gastric cancer. A total of 27 patients who received SOX as the first-line chemotherapy in our hospital were considered for the study. The SOX chemotherapy schedule consisted of 1 course every 3 weeks. S-1 was administered orally, at 80-120 mg-body, every day for 14 days. Oxaliplatin was infused at 100 mg/m2 on day 1 of each course. The median number of treatment courses was 7. The response rate and disease control rate were 47.6% and 76.2%, respectively. The observed adverse events of Grade 3 or more included neutropenia(33.3%); peripheral neuropathy and anorexia(11.1%); thrombocytopenia(7.4%); and anemia, diarrhea, fatigue, and hypercalcemia(3.7%). The median overall survival was not achieved, and the 1-year survival rate was 63.2%. Therefore, SOX is an effective and feasible first-line chemotherapy that is easily available for ambulatory treatment of patients with metastatic/recurrent gastric cancer.
要旨
進行再発胃癌に対する一次治療としてのS-1+oxaliplatin(SOX)療法の有効性と安全性について検討した。対象は当科でSOX療法を施行した進行再発胃癌27例である。投与方法はoxaliplatin 100 mg/m2を第1日目に点滴静注,S-1 80～120 mg/bodyを2週投与1週休薬で投与し,3週1コースとした。投与コース中央値は7コースで,奏効率47.6%,病勢コントロール率は76.2%であった。Grade 3以上の有害事象は,好中球減少33.3%,末梢神経障害,食欲不振11.1%,血小板減少7.4%,貧血,下痢,疲労,高カルシウム血症を3.7%に認めた。生存期間中央値には到達せず,1年生存率は63.2%であった。実地臨床においてもSOX療法の治療効果は良好で,外来で安全に施行可能であった。